Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection

Microb Cell. 2019 Feb 8;6(3):142-159. doi: 10.15698/mic2019.03.670.

Abstract

Infections by the pathogenic yeasts Candida albicans and Candida glabrata are among the most common fungal diseases. The success of these species as human pathogens is contingent on their ability to resist antifungal therapy and thrive within the human host. C. glabrata is especially resilient to azole antifungal treatment, while C. albicans is best known for its wide array of virulence features. The core mechanisms that underlie antifungal resistance and virulence in these pathogens has been continuously addressed, but the investigation on how such mechanisms evolve according to each environment is scarcer. This review aims to explore current knowledge on micro-evolution experiments to several treatment and host-associated conditions in C. albicans and C. glabrata. The analysis of adaptation strategies that evolve over time will allow to better understand the mechanisms by which Candida species are able to achieve stable phenotypes in real-life scenarios, which are the ones that should constitute the most interesting drug targets.

Keywords: antifungal resistance; biofilm formation; fungal pathogens; hostpathogen interaction; microevolution; virulence.

Publication types

  • Review

Grants and funding

Work conducted in this field has been financially supported by “Fundação para a Ciência e a Tecnologia” (FCT) (Contracts PTDC/BBB-BIO/4004/2014 and PTDC/BII-BIO/28216/2017 and PhD scholarships to PP, MG and MC, associated to the BIOTECNico and AEM FCT PhD programs). Funding received from FCT (grant UID/BIO/04565/2013) and Programa Operacional Regional de Lisboa 2020 (project no. 007317) is also acknowledged.